Procter & Gamble Health Ltd
PGHL Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #69 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
2 of 4 strong
The short version
- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization. - The company is confident in sustaining and continuing its growth momentum driven by investments in product superiority, innovation, and productivity.
From Procter & Gamble Health Ltd's Q4 FY26 earnings-call transcript · updated 30 Jun 2026.
Revenue & Sales Performance
- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization.
- Expect balanced growth through strong brand fundamentals, superior retail execution, new user acquisition, and product innovations.
- Recorded mid-single digit volume growth in FY26, with innovations contributing early single-digit points of growth.
- Poised for sustained double-digit sales growth, supported by increasing health consciousness and expanding VMS market in India.
- Export business showing strong potential with 3X growth in Nepal and high single-digit growth in Sri Lanka, adding to overall growth prospects.
- E-commerce channel rapidly growing and material, contributing to sales growth alongside traditional retail.
2 more points from Procter & Gamble Health Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Procter & Gamble Health Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Procter & Gamble Health Ltd said on order book & pipeline — free account, 30 seconds.
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q1 FY27 results?
- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization. - The company is confident in sustaining and continuing its growth momentum driven by investments in product superiority, innovation, and productivity.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.5 with a market cap of ₹8,660. Investors should review the full earnings analysis for detailed insights.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.